[mc4wp_form id="313"]

New Option Soon for Some European Patients With Leukemia

Share this post

Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
International Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply